ESLA

Estrella Immunopharma Inc

0.5290

Sep 18 • 3:59 PM ET +0.0030 (0.57%)

0.5200

Aftermarket • 7:34 PM ET -0.0090 (-1.70%)

Healthcare Biotechnology USA Nano NASD

Peers: BYSI EXOZ IBO CING FBIO IBIO ICCC IMA IMMP XBIT

| Held by: VTI VXF IWC

Scroll to Statements

Index	-
Market Cap	23.01M
Enterprise Value	22.86M
Income	-10.01M
Sales	0.00M
Book/sh	-0.17
Cash/sh	0.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Sep 14, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	153.40
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.20
Current Ratio	0.20
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-0.25
EPS next Y	-
EPS next Q	-0.08
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	-27.10% -70.08%
Sales past 3/5Y	- -
EPS Y/Y TTM	24.03%
Sales Y/Y TTM	-
EPS Q/Q	65.04%
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	0.00% -

Insider Own	60.42%
Insider Trans	0.01%
Inst Own	11.02%
Inst Trans	-1.32%
ROA	-416.74%
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-20.49%
SMA50	-26.84%
SMA200	-53.82%
Trades

Shs Outstand	43.03M
Shs Float	17.22M
Short Float	0.68%
Short Ratio	2.91
Short Interest	0.12M
52W High	3.15 -83.21%
52W Low	0.51 3.73%
Volatility	16.76% 12.35%
ATR (14)	0.08
RSI (14)	27.26
Beta	0.92
Rel Volume	1.43
Avg Volume	40.32K
Volume	57,686

Perf Week	-19.80%
Perf Month	-28.20%
Perf Quarter	-44.32%
Perf Half Y	-51.91%
Perf YTD	-66.09%
Perf Year	-52.77%
Perf 3Y	-95.48%
Perf 5Y	-94.60%
Perf 10Y	-
Recom	1.00
Target Price	12.00
Prev Close	0.53
Price	0.53
Change %	0.57%

Aug-11-26 08:00AM	Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkins Lymphoma (Business Wire)
Aug-03-26 08:00AM	Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma (Business Wire)
Jul-29-26 08:00AM	Estrella Immunopharma Activates Baylor Scott & White Research Institute as Second Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma (Business Wire)
Jul-24-26 08:00AM	Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkins Lymphoma (Business Wire)
May-05-26 08:00AM	Estrella Immunopharma to Participate in the D. Boral Capital Global Conference (Business Wire) -8.07%
08:00AM	Loading…
Mar-23-26 08:00AM	Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research (Business Wire)
Feb-09-26 07:00AM	Estrella Immunopharma Presents Promising Updated Data on EB103 in Oral Presentation at the 2026 Tandem Meetings of ASTCT & CIBMTR (Business Wire)
Feb-03-26 08:00AM	Estrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT & CIBMTR (Business Wire) +7.34%
Jan-05-26 08:30AM	Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (Business Wire)
Dec-04-25 08:00AM	Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation (Business Wire) +12.21%
Nov-04-25 12:13PM	Top 100 Stocks to Buy: Two Penny Stocks Moved Up 51 Spots. Should You Buy Either? (Barchart) -24.92%
Nov-03-25 08:00AM	Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients (Business Wire) +26.03%
Oct-06-25 08:00AM	Estrella Immunopharma Regains Compliance with Nasdaq Listing Requirements (Business Wire) +6.87%
Jun-05-25 08:00AM	Estrella Immunopharma Announces Activation of Additional Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma (Business Wire) +7.07%
Jun-03-25 08:00AM	Estrella Immunopharma Announces Approximately $3.35 Million Private Placement Equity Financing (Business Wire) -14.00%
11:15PM	Loading…
May-29-25 11:15PM	Estrella Immunopharma, Inc. (ESLA) Doses First Patient in Higher-Dose Cohort of EB103 Phase I/II Trial (Insider Monkey) +5.15%
08:01AM	Estrella Immunopharma Initiates Second Cohort and Doses First Patient in STARLIGHT-1 Trial of EB103 in Advanced B-Cell Non-Hodgkins Lymphomas (Business Wire)
Mar-05-25 08:00AM	Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners (Business Wire)
Feb-22-25 08:55AM	Estrella Immunopharma completes first dose cohort in STARLIGHT trial (TipRanks)
Feb-21-25 08:30AM	Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort (Business Wire)
Feb-19-25 04:46PM	Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital (Business Wire) +8.76%
Sep-27-24 12:00PM	Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS T-cells (Business Wire) +22.69%
Aug-14-24 12:00PM	Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member (Business Wire)
Aug-02-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -18.08%
May-20-24 10:52AM	ESLA Stock Earnings: Estrella Immunopharma Reported Results for Q3 2024 (InvestorPlace)
Sep-29-23 10:34AM	TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination (PR Newswire) -6.22%
Sep-18-23 05:00PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire) +34.29% -17.25%
Aug-18-23 04:30PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire)
Jul-18-23 04:30PM	TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination (PR Newswire)
Jul-12-23 07:00AM	TradeUP Acquisition Corp. Announces Meeting Date for Stockholders to Approve the Business Combination with Estrella Biopharma, Inc. and Liquidation of Investments Held in the Trust Account into Cash (PR Newswire)

Estrella Immunopharma, Inc. operates as a pre-clinical stage biopharmaceutical company, which engages in the development of T-cell therapies for patients with cancers and autoimmune diseases. The company was founded on March 30, 2022 and is headquartered in Emeryville, CA.

CEODr. Cheng Liu Ph.D.

Chief Financial OfficerMr. Jiandong Xu

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Liu Cheng	CEO	Aug 25 '26	Option Exercise	0.81	100,000	81,500	397,437	Aug 26 07:23 PM
Xu Jiandong	Chief Financial Officer	Aug 18 '26	Option Exercise	0.81	100,000	81,500	365,488	Aug 25 09:55 PM
Xu Jiandong	Chief Financial Officer	Oct 07 '25	Buy	1.33	1,000	1,330	265,488	Apr 29 09:36 PM
Xu Jiandong	Chief Financial Officer	Sep 22 '25	Buy	1.16	1,000	1,160	16,700	Apr 29 09:36 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ESLA

Estrella Immunopharma Inc

Upgrade your Finviz experience